Osteoporosis Update Monica Clark Osteoporosis Nurse Description A - - PowerPoint PPT Presentation

osteoporosis update
SMART_READER_LITE
LIVE PREVIEW

Osteoporosis Update Monica Clark Osteoporosis Nurse Description A - - PowerPoint PPT Presentation

Osteoporosis Update Monica Clark Osteoporosis Nurse Description A reduction in bone mass with micro architectural deterioration in bone tissue leading to increase in fracture risk Fragility by loss of structure and reduced


slide-1
SLIDE 1

Osteoporosis Update

Monica Clark Osteoporosis Nurse

slide-2
SLIDE 2

Description

  • A reduction in bone mass
  • with micro architectural deterioration in bone

tissue leading to increase in fracture risk

  • Fragility by loss of structure and reduced

mechanical strength.

  • Fragility fractures are fractures that result

from mechanical forces that would not

  • rdinarily result in fracture : a fall from

standing height.

slide-3
SLIDE 3

Causes

  • Ageing
  • Genes/ family history / frame / inherited conditions
  • Hormone status ( male + females) early menopause
  • Medications: steriod use, breast / prostate cancer

treatments, Epilepsy medications

  • Medical conditions. Thyroid excess, PTH excess, renal

disease

  • Absorption problems; Coeliac, small bowel disease.

Anorexia, gastric surgery.

  • Lifestyle, smoking, alcohol excess, reduced exercise,

longstanding poor nutrition

  • Immobility, pregnancy, vitamin D deficiency
slide-4
SLIDE 4

Falls and fracture care and prevention A road map for a systematic approach

Hip fracture patients

Objective 1: Improve outcomes and improve efficiency of care after hip fractures – by following the 6 “Blue Book” standards

Non-hip fragility fracture patients

Objective 2: Respond to the first fracture, prevent the second – through Fracture Liaison Services in acute and primary care

Individuals at high risk of 1st fragility fracture or other injurious falls

Objective 3: Early intervention to restore independence – through falls care pathway linking acute and urgent care services to secondary falls prevention

Older people

Objective 4: Prevent frailty, preserve bone health, reduce accidents – through preserving physical activity, healthy lifestyles and reducing environmental hazards

Stepwise implementation - based on size

  • f impact

Department of Health Prevention Package for Older People: Falls and Fractures - Effective interventions in health and social care

slide-5
SLIDE 5

Fragility fracture through the life span1

  • 1. J Endocrinol Invest 1999;30:583-588 Kanis JA & Johnell O
  • 2. Osteoporosis Review. 2009;17(1):14-16 Mitchell PJ

“Hip fracture is all too often the final destination of a 30 year journey fuelled by decreasing bone strength and increasing falls risk”2

Morbidity attributable to ageing alone Additional morbidity due to fragility fracture event

slide-6
SLIDE 6

FRAX : combines risks +/_ BMD and

  • ffers recommendations
  • Benefits
  • Web-based
  • Easy to use
  • 10 year projection
  • Recommendation

allied with N.O.G.G

  • Drawbacks
  • 10 year risk
  • Under estimates

treatment elderly

  • Over estimates in

younger women

slide-7
SLIDE 7

Current Treatments

  • Anti resorption therapy: Bisphosphonates, (oral .

I.V), Denosumab (s/c)

  • DABA: (Dual action bone agent) -Strontium

Ranelate , ( oral)

  • Bone building therapy. Teriperatide ( s/c)
  • HRT: Bone maintanence.
  • Supplements, : calcium/ vitamin D, & vitamin D
slide-8
SLIDE 8

Bisphosphonates

  • Different degrees of

potency.

  • Suppresses both
  • steoblast and osteoclast

function

  • Evidence of contiuned use
  • n cessation of

treatment.

  • Common as muck, cheap

as chips!!

  • Problems
  • Long term suppression

beyond therapeutic

  • effect. Accrurel of

microdamage within bone

  • Atypical fractures
  • Osteonecrosis of the jaw
  • Can cause severe

problems with gullet

slide-9
SLIDE 9

Strontium Ranelate

  • Unknown true

mechanism of action- some weak osteoblast stimulation

  • Adds Strontium into

skeleton, big increase in BMD

  • Pain to take!!
  • Increased risk of cardio

vascular events

  • Nausea,
  • Diarrhoea in 30% of

patients.

slide-10
SLIDE 10

Teriparitide

  • Pulsed PTH dose
  • Increases bone

formation over bone resorption

  • Excellent increases in

BMD at spine and significantly reduces vertebral fracture rates in patients at very high risk.

  • 2 year treatment plan.
  • ( bone cancer)- need to

follow up with alternative agent

  • s/c Injection every day
  • Usually well tolerated
  • Relatively expensive so

restrictions are quite stringent

slide-11
SLIDE 11

Denosumab

  • Monoclonal antibody to
  • steoclast activity,
  • Very specific mode of

action.

  • Can be used with

patients with compromised renal function but...

  • Shared care agreement

with GP’s

  • 6 monthly s/c
  • Swift Offset time
  • Follow on therapy after

completing course

  • Can drop serum calcium

and cause severe hypocalcaemia

slide-12
SLIDE 12

New Treatments

  • Cathepsin K: promotes osteoclast activity.
  • Enzyme Cathepsin K involved in breakdown
  • f collegen and allows breakdown of cartiledge and

bone

  • Ondancatib is an antagonist to Cathepsin K and inhibits

bone resorption

  • Reduces bone resorption and results in increases in

trabecular and corticol BMD.

  • Significant reduction fractures at 3 years vertebral 54%,

non- vertebral 23% , hip 47%.

slide-13
SLIDE 13

Sclerostin

  • Targets osteoclasts- 90% of all bone cells..

Sclerostin has anti anabolic effect on bone formation and is bone specific.

  • Target Sclerostin with antibody Romosozumab

/ Blosozumab – to have powerful effect on bone formation.

  • Short lived effect and fast off set time.
  • Use powerful effect, then switch to other

therapies to see continuation of improvement.

slide-14
SLIDE 14

Current Issues

  • Atypical femoral fractures (A.F.F.)
  • Rate: 11 per 10,000 with 4-5 years use
  • Rate: Hip fracture 155 per 10,000.
  • Long term use of anti resorptives , Alendronic

acid , Denosumab.

  • Pain pro dromal
  • Spontaneous fracture
  • Beaking of corticol surface. Often noted on lateral

cortex first. Localised thickening of cortex

  • Often bilateral
slide-15
SLIDE 15
slide-16
SLIDE 16

Vertebral fracture

  • Generally underestimated but significant
  • fractures. 30% come to light.
  • Powerful predictors of future fracture. Also allow

treatment at lower BMD.

  • Often clinically silent : back pain
  • Description issues at reporting ( when a fracture

is not called a fracture)

  • Can be identified opportunistically. X-ray, MRI,

C.T, Barium studies.

slide-17
SLIDE 17

Nutritional requirements of supplements

  • National Recommendations for calcium intake

700mg per day ( equiv 1pint milk)

  • Osteoporosis. Up to 1200mg. Reflected in

supplements dose

  • Vitamin D: 10ug/ 400IU / day
  • Safe access to sun exposure
  • Foods provide up to 15% vitamin D intake, oily

fish, fortified margarines & cereals, egg yolk.

  • Best advice is Healthy Plate.
slide-18
SLIDE 18

Eat well plate: its all about a healthy balanced diet.

slide-19
SLIDE 19

Dietary Sources of Vitamin D

slide-20
SLIDE 20

Healthy advice

  • Stop smoking
  • Cigarettes causes early

death and imperfect functioning of bone cells

  • Additional benefits
  • Good for exercise

capacity

  • Good for general cardio

vascular health

  • Reduce alcohol use
  • 3+ alcoholic drinks per

day

  • Damages / reduces liver

health

  • Increases Falls risk
  • Risk in Elderly across

health generally.

slide-21
SLIDE 21